The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Vertex Pharmaceuticals' suzetrigine is an investigational ... Alyftrek is yet another improvement from its latest gem, Trikafta. Among other things, Alyftrek is just as effective despite its ...
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
Vertex Pharmaceuticals' suzetrigine is an investigational ... enhances patient benefit compared to the blockbuster drug Trikafta. Vertex has won two cystic fibrosis approvals from the FDA, but ...
Vertex Pharmaceuticals Incorporated (Nasdaq ... and lower sweat chloride levels than TRIKAFTA, is another step in achieving this goal.” “In Phase 3 clinical trials, across a broad range ...